Objectives: Phosphodiesterase (PDE) III inhibitor therapy is effective for treatment of acute decompensated heart failure (ADHF). Nevertheless, this drug is expensive than conventional inotropic agent dobutamine. We compared total medication costs of the patients treated with PDE III inhibitor amrinone therapy to that of the patients treated with conventional dobutamine therapy during initial hospitalization. Methods: We analyzed 160 consecutive patients with ADHF admitted to our hospital. Shock, dehydration, severe infection, multiple organ failure, and mild heart failure (New York Heart Association class IIs) were not eligible for the study. Ninety-seven patients were divided into two groups: 1) DOB group treated with dobutamine therapy; and 2) AMR group treated with amrinone therapy. Total medication costs and cost for hospital room charge were calculated based on their usage during the initial hospitalization for each patient.
Introduction
Intravenous inotropic agents are still on the first-line treatment for acute decompensated heart failure (ADHF) in emergency departments in developed countries. Long-term use of inotropic agent dobutamine was reported to deteriorate clinical course of ADHF [1] . Recently, phosphodiesterase (PDE) III inhibitor milrinone has been reported to fail to lower mortality in acute heart failure [2] . Drug cost was higher for the patients treated with milrinone than for the patients treated with dobutamine because of higher price of milrinone [3] . On the other hand, nesiritide is a promising brain-type natriuretic peptide for acute heart failure. Despite of its higher price, nesiritide provided lower mortality [4] and lower cost of treatment [5, 6] than milrinone did in the setting of ADHF. It is explained by shortening of length of stay which is realized by nesiritide's appropriate therapeutic action on ADHF [5, 6] .
Medical effects of amrinone for ADHF were already published in previous journals [7] [8] [9] . We think PDE III inhibitor amrinone has appropriate therapeutic action on ADHF comparing with inotropic agent dobutamine, though unit cost per dose of amrinone (49.11 yen/mg) was higher than that of dobutamine (19.48 yen/mg). We assumed that total medication costs of drugs might be cheaper if we appropriately utilize costly drug for the treatment of acute de-compensated heart failure. Thus, we compared total medication costs during initial hospitalization in the ADHF patients treated with amrinone therapy to that in the patients treated with dobutamine therapy in our hospital.
Methods

Patient Eligibility
We analyzed 160 consecutive patients with ADHF admitted to our hospital from August 1995 to July 1998. Thirty-three patients were excluded from the study because of shock (n = 5), dehydration (n = 20), severe infection (n = 6) and multiple organ failure (n = 2). Then 30 patients with mild heart failure (New York Heart Association [NYHA] class IIs) were excluded. The remaining 97 patients (61 men and 36 women; mean age 65.2 Ϯ 10.8 years) with moderate to severe heart failure (NYHA class IIm and III) were enrolled in the study. The study procedures were in accordance with the guidelines of our hospital, and informed consent was obtained from each patient. We arbitrarily allocated of the patients to dichotomized regimens. There were two senior house officers in charge of patient care decision during the study period. One (TS) always independently used amrinone (AMR) and the other (HM) always independently used dobutamine (DOB). These two doctors took charges alternately, and made dichotomized treatment groups. Eventually, there were no differences in clinical background between the two groups except intravenous regimens. We defined the group treated with intravenous DOB as the DOB group (n = 48). We defined the other group treated with intravenous AMR as the AMR group (n = 49). We did not change the dose of basal oral medications. As additional diuretics, we used intravenous furosemide (30-660 mg/day) with dobutamine in the DOB group. And we used intravenous atrial natriuretic peptide (0.05-0.2 mg/kg/min) with amrinone as additional diuretics in the AMR group.
Cost Consequence Study
We conducted a cost consequence study from a hospital perspective. We manually collected each patient data from his or her charts during the initial hospitalization. We calculated medical expenditure based on the charts according to piecework payment system in Japan during the study period. Japan has a system of universal health coverage, whereby most of the population is enrolled in some form of health insurance scheme and are thus required to pay insurance premiums. Fees for medical services are standardized nationwide by the Medical Fee Table and those for drugs by the national health insurance (NHI) drug price list. Health insurance provides reimbursement only for those drugs listed in the NHI drug price list. Price list for drugs and medical devices, and other medical procedures is determined by national government.
Cost of intravenous drugs was calculated based on drug usage during the initial hospitalization for each patient. Total medication cost including oral drugs and cost for hospital room charge were also calculated based on their usage during the initial hospitalization for each patient. Average costs were determined for each group. We compared those average costs and length of stay between the DOB and AMR groups.
Intravenous drug prices were as follows: 1) furosemide 40 mg 1 ampule = 64 yen; 2) furosemide 100 mg 1 ampule = 223 yen; 3) dobutamine 100 mg 1 ampule = 1948 yen; 4) dobutamine 200 mg 1 vial = 3922 yen; 5) dobutamine 600 mg 1 vial = 8255 yen; 6) amrinone 50 mg 1 ampule = 2872 yen; 7) amrinone 100 mg 1 ampule = 4911 yen; and 8) carperitide 1000 mg 1 vial = 3344 yen.
Rates of hospital room charge were as follows: 1) 1651 yen/day (within 2 weeks); 2) 1420 yen/days (over 2 weeks and within 1 month): 3) 1215 yen/day (over 1 month and within 3 months); 4) 1127 yen/day (over 3 months and within 6 months); and 5) 1095 yen/day (over 6 months).
Results were presented as mean Ϯ SD for continuous variables. Data were statistically analyzed with JMP statistical software (JMP version 5.1, SAS Institute, Cary, NC). Differences for continuous variables were estimated by Wilcoxon signed-rank test (MannWhitney U-test). Differences for categorical variables were estimated by Fisher's exact test or chi-square test, as appropriate. A value of P < 0.05 was considered significant.
Results
Patient Characteristics
Age, sex, etiology of heart failure, and oral medication were similar among the three groups (Table 1) . Severity of heart failure, i.e., NYHA class was similar between the DOB and AMR groups. Left ventricular ejection fraction (LVEF) determined by echocardiography on admission was also similar between the DOB and AMR groups.
Length of Stay and Cost of Drugs
Mean length of stay for initial hospitalization was 27.6 Ϯ 31.9 days in the DOB group and 6.1 Ϯ 4.2 days in the AMR group. Length of stay was longer in the DOB group than in the AMR group (Fig. 1a) . Mean accumulated doses of intravenous drugs were 8868 Ϯ 12,233 mg of dobutamine and 199 Ϯ 379 mg of furosemide in the DOB group, and 3210 Ϯ 2399 mg of amrinone and 471 Ϯ 352 mg of hANP in the AMR group. Mean calculated cost of intravenous drugs was higher in the DOB group (173,186 Ϯ 239,147 yen) than in the AMR group (63,145 Ϯ 47,223 yen, P < 0.05) (Fig. 1b) . Total medication cost was higher in the DOB group (186,599 Ϯ 238,903 yen) than in the AMR group (73,335 Ϯ 46,327 yen, P < 0.05) (Fig. 1c) . Cost for hospital room charge was higher in the DOB group (64,215 Ϯ 44,963 yen) than in the AMR group (32,951 Ϯ 12,495 yen, P < 0.05) (Fig. 1d) .
Adverse Events
Although minor adverse events including renal dysfunction (elevation in serum creatinine more than 1.5 mg/dL and less than 3.0 mg/dL) (nine patients in DOB, one patient in AMR), serum Na lowering (three patients in DOB, one patient in AMR), and nonsustained ventricular tachycardia (one patient in DOB, 0 in AMR) were observed in the clinical course; all of those events were reversible. Nevertheless, event rate of renal dysfunction was higher in the DOB group than in the AMR group (P < 0.001). In this study, all the patients were able to be discharged and no patient died.
Discussion
Patient Background
Our results suggested that expensive amrinone therapy resulted in inexpensive cost of drugs and cost of hospital stay relative to conventional dobutamine therapy. On the contrary, Yamani et al. reported that treatment of ADHF with milrinone was expensive compared to that with dobutamine [3] . In their study, subjects were sicker patients including NYHA class IV and lower mean LVEF of 18% [3] . Then, milrinone did not shorten the length of stay, and the treatment with milrinone became expensive [3] . Our subjects were less sick patients with class IIm or III and mean LVEF of 32%. Therefore, in-hospital mortality was 9% in their study, while that was 0% in our study. Differences in the seriousness of the subjects might affect the differences in the outcome and hence the differences in costs. Aranda et al. also reported that milrinone therapy for severely ill patients did not shorten length of stay as compared to dobutamine, although in-hospital mortality was similarly low in both treatments [10] . Thus, total medication cost of the milrinone group was higher than that of the dobutamine group [10] .
Levinoff Roth et al. found amrinone was effective for refractory heart failure (NYHA class III and IV) patients [11] . Nevertheless, they compared intravenous amrinone with conventional oral therapy. Amrinone may be more cost-effective in severer patients (NYHA class IV). Nevertheless, we only ana- * Figure 1 (a) Length of stay was longer in the DOB group than in the AMR group (*P < 0.05); (b) Mean calculated cost of intravenous drugs was higher in the DOB group than in the AMR group (*P < 0.05); (c) Total medication cost was higher in the DOB group than in the AMR group (*P < 0.05); (d) Cost for hospital room charge was higher in the DOB group than in the AMR group (*P < 0.05). AMR, amrinone; DOB, dobutamine.
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Limitations
As mentioned above, this study did not involve severer patients. Thus, we did not experience the extension of length of stay because of deterioration of heart failure. And hence, we did not experienced major adverse effects of amrinone, i.e., sustained ventricular tachycardia or hypotension. We only analyzed the cost for initial hospitalization and did not include cost for rehospitalization. If we calculated the costs for drugs or hospitalization for a certain fixed period like 1 or 2 years after the admission, cost for amrinone therapy might have changed. This is not a prospective randomized controlled trial. Although, the study patients had similar oral medications and clinical background, we cannot deny a selection bias in the study background. It was tremendously difficult to conduct a randomized controlled cost comparison in the study period, because we did not have sophisticated online payment database system in Japan.
Recently, Diagnosis Procedure Combination, a Japanese version of Diagnostic Related Groups-based Prospective Payment System has become widespread and commonly used in Japanese hospitals. According to this new precision system, the cost for hospital stay might be different from the present conclusion. Nevertheless, favorable effects of amrinone on clinical courses of moderately to severely ill patients could shorten the length of stay and could lessen acquisition cost of amrinone even in the new payment system.
Conclusion
Amrinone therapy shortened length of stay in a subgroup of the Japanese patients with ADHF compared to that in the patients treated with conventional dobutamine therapy. In this study, total medication cost and cost for hospital room charge were relatively inexpensive in the patients treated with amrinone therapy as compared to those treated with dobutamine therapy in spite of higher prices of amrinone treatment. In the treatment of ADHF, appropriate therapy even with expensive drugs makes total medication costs less expensive comparing with conventional therapy with cheaper drugs during initial hospitalization.
